Cancer Cell-2016-Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
本文檔由 Science 分享于2016-06-17 11:02
暫無簡介
下載文檔
收藏